12:00 AM
May 07, 2015
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Glucokinase (GCK; GK); glucokinase regulator (GCKR; GKRP)

Endocrine/metabolic disease


In vitro and rat studies suggest a thiazole sulfone-based disruptor of the GCK-GCKR complex could help treat Type II diabetes. Chemical synthesis and in vitro testing of aryl sulfone analogs identified a lead thiazole sulfone that inhibited GCK-GCKR binding with an IC50 of 6...

Read the full 212 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >